Sotrastaurin (AEB071) alone and in combination with cyclosporine a prolongs survival times of non-human primate recipients of life-supporting kidney allografts

Transplantation

Volumn 93, Issue 2, 2012, Pages 156-164

  Bigaud, Marc ^a   Wieczorek, Grazyna ^a   Beerli, Christian ^a   Audet, Maxime ^b   Blancher, Antoine ^c   Heusser, Christoph ^a   Morris, Randall E ^a   Wagner, Jürgen ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

AEB071; Immunosuppression; Kidney; Non human primate; Protein kinase C; Sotrastaurin; Transplant

Indexed keywords

CYCLOSPORIN A; SOTRASTAURIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPATHOLOGY; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIFE SUPPORTING KIDNEY ALLOGRAFT; MACACA FASCICULARIS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CYCLOSPORINE; DRUG SYNERGISM; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRROLES; QUINAZOLINES; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855847119     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823cf92f     Document Type: Article

References (27)

1. Tang IY, Meier-Kriesche H-U, Kaplan B. Immunosuppressive strategies to improve outcomes of kidney transplantation. Semin Nephrol 2007; 27: 377.
2. Vincenti F, Kirk AD. What's next in the pipeline.AmJ Transplant 2008; 8: 1972.
3. Tan SL, Parker PJ. Emerging and diverse roles of protein kinase C in immune cell signaling. Biochem J 2003; 376(pt 3): 545.
4. Baier G. The PKC gene module: Molecular biosystematics to resolve its T cell functions. Immunol Rev 2003; 192: 64.
5. Baier G, Wagner J. PKC inhibitors: Potential in T-cell dependent immune diseases. Cur Opinion Cell Biol 2009; 21: 262.
6. Matz M, Weber U, Mashreghi MF, et al. Effects of the new immunosuppressive agent AEB071 on human immune cells. Nephrol Dial Transplant 2010; 25: 2159.
7. Cooper JE, Wiseman AC. Novel immunosuppressive agents in kidney transplantation. Clin Nephrol 2010; 73: 333.
8. Wagner J, von Matt P, Sedrani R, et al. Discovery of 3-(1H-indol-3-yl)-4- [2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. J Med Chem 2009; 52: 6193.
9. Evenou JP, Wagner J, Zenke G, et al. The potent protein kinase Cselective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther 2009; 330: 792.
10. Weckbecker G, Pally C, Beerli C, et al. Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. Transpl Int 2010; 23: 543.
11. Fang YH, Joo DJ, Lim BJ, et al. AEB-071 versus tacrolimus monotherapy to prevent acute cardiac allograft rejection in the rat: A preliminary report. Transplant Proc 2010; 42: 976.
12. Bigaud M, Wieczorek G, Riesen S, et al. NVP-AEB071, a novel oral inhibitor of early T-cell activation, prolongs the survival of non-human primate kidney allografts when used as monotherapy or at non-effective doses combined with non-effective dose of cyclosporine [abstract 546]. Am J Transplant 2006; 6(suppl 2): s250.
13. Weckbecker G, Jean C, Pally C, et al. Pharmacokinetics (PK) of the novel oral Protein Kinase C (PKC) inhibitor NVP-AEB071 in rats and non-human primates: Study of immunosuppressive efficacy and distribution to lymphatic organs [abstract 2114]. Am J Transplant 2006; 6(S2): S768.
14. Schuurman HJ, Menninger K, Audet M, et al. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD. Transplantation 2002; 74: 951.
15. Quesniaux V, Menninger K, Audet M, et al. FTY-720 is efficacious in monkey kidney transplantation. Transplant Proc 2001; 33: 2374.
16. Kovarik JM, Stitah S, Slade A, et al. Sotrastaurin and tacrolimus coadministration: Effects on pharmacokinetics and biomarker responses. J Clin Pharmacol 2010; 50: 1260.
17. Kovarik JM, Bartlett M, Rordorf C, et al. Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration. Int J Clin Pharmacol Ther 2010; 48: 103.
18. Bigaud M, Wieczorek G, Preussing E, et al. NVP-AEB071 (AEB), the novel oral inhibitor of protein kinase C (PKC) and early T-cell activation, prolongs non-human primates (NHP) kidney allograft survival when combined with everolimus (RAD), ERL080 (ERL) or FTY720 (FTY) without calcineurin inhibitor (CNI) [abstract 550]. Am J Transplant 2006; 6(suppl 2): s251.
19. Bigaud M, Maurer C, Vedrine C, et al. A simple method to optimize peripheral blood mononuclear cell preparation from cynomolgus monkeys and improve mixed lymphocyte reactions. J Pharmacol Toxicol Methods 2004; 50: 153.
20. Schuler W, Bigaud M, Brinkmann V, et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 2004; 77: 717.
21. Gaschen L, Schuurman HJ. Ultrasound score is more predictive than serum creatinine in assessment of cellular rejection in cynomolgus monkey renal allografts. Invest Radiol 2002; 37: 376.
22. Montgomery SP, Mog SR, Xu H, et al. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. Am J Transplant 2002; 2: 381.
23. Blancher A, Tisseyre P, Dutaur M, et al. Study of Cynomolgus monkey (Macaca fascicularis) MhcDRB (Mafa-DRB) polymorphism in two populations. Immunogenetics 2006; 58: 269.
24. Gaschen L, Kunkler A, Menninger K, et al. Safety of percutaneous ultrasound-guided biopsy of renal allografts in the cynomolgus monkey: Results of 348 consecutive biopsies. Vet Radiol Ultrasound 2001; 42: 259.
25. Wieczorek G, Bigaud M, Menninger K, et al. Acute and chronic vascular rejection in nonhuman primate kidney transplantation.AmJ Transplant 2006; 6: 1285.
26. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
27. Solez K, Colvin RB, Racusen LC, et al. Banff 07classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.